Spots Global Cancer Trial Database for dose escalation
Every month we try and update this database with for dose escalation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC) | NCT00960167 | Hepatocellular ... | 3DCRT or IMRT | 18 Years - 70 Years | National Taiwan University Hospital | |
| A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors | NCT05764915 | Advanced Solid ... | RGT-264 phospha... | 18 Years - 80 Years | Regor Pharmaceuticals Inc. | |
| Safety Study of FLP Injection to Treat Tumor Patients | NCT01361529 | Advanced Cancer | FLP,dose escala... | 18 Years - 70 Years | Acea Bio (Hangzhou) Co., Ltd. | |
| Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours | NCT00697879 | Solid Tumor | CHR-3996 | 18 Years - | Chroma Therapeutics | |
| First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | NCT03681951 | Neoplasms, Panc... | GSK3145095 Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors | NCT00842335 | Advanced Solid ... | JI-101 | 18 Years - | Jubilant Innovation Ltd. | |
| Dose Escalated Adaptive RadioTherapy in Definitive Chemo-radiotherapy for Esophageal Cancer | NCT04086901 | Esophageal Canc... | Radiotherapy do... | 18 Years - | University of Aarhus | |
| A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC | NCT01957007 | Solid Tumors | Docetaxel vantictumab | 18 Years - 90 Years | Mereo BioPharma | |
| Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | NCT02367352 | Advanced Solid ... Ovarian Cancer Small Cell Lung... | Alisertib Paclitaxel | 18 Years - | Takeda | |
| A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer | NCT04514159 | Breast Cancer | ZN-c5 Abemaciclib | 18 Years - | Zeno Alpha Inc. | |
| A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors | NCT03266159 | Solid Tumours | GSK525762 Besyl... Trametinib tabl... | 18 Years - | GlaxoSmithKline | |
| Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors | NCT01065623 | Neoplasms | BAY79-4620 | 18 Years - | Bayer | |
| Dose Escalation Using Fiducial Markers in Image Guided Volumetric Modulated Arc Therapy to the Focal Lesion Micro Boost of Localized Prostate Cancer | NCT03384199 | Prostatic Adeno... | Dose escalation... | 40 Years - 80 Years | Kasr El Aini Hospital | |
| First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors | NCT01881217 | Neoplasms | BAY1179470 | 20 Years - | Bayer | |
| An Investigation of TAS-119 Monotherapy | NCT02448589 | Advanced Solid ... | TAS-119 | 18 Years - | Taiho Oncology, Inc. | |
| BAY1238097, First in Man | NCT02369029 | Neoplasms | BAY 1238097 | 18 Years - | Bayer | |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | NCT03058289 | Breast Cancer Head and Neck C... Squamous Cell C... Lymphoma Pancreatic Canc... Liver Cancer Colon Cancer Lung Cancer Bile Duct Cance... Chordoma of Sac... Sarcoma | INT230-6 anti-PD-1 antib... anti-CTLA-4 ant... | 18 Years - | Intensity Therapeutics, Inc. | |
| Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer | NCT03916510 | Locally Advance... | Enadenotucirev Capecitabine Radiotherapy | 18 Years - | University of Oxford | |
| A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | NCT02236000 | Breast Cancer | Neratinib T-DM1 | 18 Years - | NSABP Foundation Inc | |
| Evaluation of KX2-391 in Patients With Advanced Malignancies | NCT00658970 | Solid Tumors Lymphoma | KX2-391 | 18 Years - | Athenex, Inc. | |
| Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 | NCT01026402 | Advanced Solid ... | AZD2014 | 18 Years - 150 Years | AstraZeneca | |
| Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | NCT02134067 | Advanced Solid ... | TAS-119 Paclitaxel | 18 Years - | Taiho Oncology, Inc. | |
| Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | NCT02316197 | Advanced Solid ... Chronic Lymphoc... | MSC2490484A (M3... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404 | NCT01240642 | Metastatic Canc... Metastatic Canc... | ASA404 | 18 Years - | Novartis | |
| A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05159700 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | NCT01677741 | Neoplasms, Brai... | Dabrafenib | 12 Months - 17 Years | Novartis | |
| FS222 First in Human Study in Patients With Advanced Malignancies | NCT04740424 | Advanced Cancer Metastatic Canc... | FS222 | 18 Years - | invoX Pharma Limited | |
| BAY1238097, First in Man | NCT02369029 | Neoplasms | BAY 1238097 | 18 Years - | Bayer | |
| Phase I Trial of BAY1251152 for Advanced Blood Cancers | NCT02745743 | Hematologic Neo... | BAY1251152 | 18 Years - | Bayer | |
| A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | NCT04957290 | Metastatic Cast... | NOX66 NOX66 NOX66 NOX66 NOX66 EBRT | 18 Years - | Noxopharm Limited | |
| Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | NCT01000896 | Cancer Non Small Cell ... Epithelial Ovar... | AZD0530 Carboplatin paclitaxel | 20 Years - | AstraZeneca | |
| First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer | NCT01723475 | Prostatic Neopl... | BAY2010112 BAY2010112 | 18 Years - | Bayer | |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | NCT04430842 | Astrocytoma Brain Cancer Brain Metastase... Bladder Cancer Breast Cancer Cervical Cancer Cholangiocarcin... Colorectal Canc... Esophagus Cance... Gastric Cancer Head and Neck C... Kidney Cancer Liver Cancer Lung Cancer Melanoma Ovarian Cancer Pancreatic Canc... Pleural Mesothe... Prostate Cancer Sarcoma Tongue Cancer Thymic Carcinom... Urinary Tract C... | QBS10072S | 18 Years - | Quadriga Biosciences, Inc. | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | NCT01703572 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT) | NCT03663218 | Prostate Cancer | Dose escalation | 18 Years - 90 Years | Weill Medical College of Cornell University | |
| Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects | NCT01340040 | Cancer Advanced Solid ... | MEDI-573 | 18 Years - | AstraZeneca | |
| A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer | NCT00058526 | Neoplasms, Brea... | Immunotherapeut... | 40 Years - 70 Years | GlaxoSmithKline | |
| A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | NCT05263180 | Advanced Solid ... | EMB-09 | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma | NCT02446574 | Esophageal Neop... | Paclitaxel Cisplatin Radiation | 18 Years - 68 Years | ChineseAMS | |
| Phase I Trial of Combination of FOLFIRI and SOM 230 | NCT01434069 | Gastrointestina... | SOM230C LAR FOLFIRI Infusio... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS) | NCT01206036 | Prostatic Neopl... | Docetaxel Temsirolimus | 18 Years - | Central European Society for Anticancer Drug Research | |
| Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer | NCT02342054 | Prostate Cancer | MRI-TRUS fusion... | 18 Years - | Hospital de Cruces | |
| Dose Escalation Using Fiducial Markers in Image Guided Volumetric Modulated Arc Therapy to the Focal Lesion Micro Boost of Localized Prostate Cancer | NCT03384199 | Prostatic Adeno... | Dose escalation... | 40 Years - 80 Years | Kasr El Aini Hospital | |
| A Study of CDX-585 in Patients With Advanced Malignancies | NCT05788484 | Non-small Cell ... Gastric Cancer Head and Neck C... Ovarian Cancer Primary Periton... Fallopian Tube ... Bladder Urothel... Colorectal Canc... Esophageal Canc... Hepatic Cancer Renal Cell Carc... Cholangiocarcin... Pancreatic Canc... Other Solid Tum... | CDX-585 | 18 Years - | Celldex Therapeutics | |
| Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | NCT02134067 | Advanced Solid ... | TAS-119 Paclitaxel | 18 Years - | Taiho Oncology, Inc. | |
| Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies | NCT01297530 | Neoplasms | BAY87-2243 | 18 Years - | Bayer | |
| Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy | NCT03253744 | Prostate Cancer Prostatic Neopl... | 18F-DCFPyL Tumor Irradiati... Prostate + tumo... Tumor Irradiati... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase 1 Study of ONT-10 in Patients With Solid Tumors | NCT01556789 | Solid Tumors | ONT-10 | 18 Years - 70 Years | Seagen Inc. | |
| A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors | NCT01277146 | Solid Tumors | OMP-59R5 | 18 Years - 90 Years | Mereo BioPharma | |
| Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy | NCT03253744 | Prostate Cancer Prostatic Neopl... | 18F-DCFPyL Tumor Irradiati... Prostate + tumo... Tumor Irradiati... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors | NCT01778439 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors | NCT04669899 | Cancer | JTX-8064 pimivalimab | 18 Years - | Jounce Therapeutics, Inc. | |
| Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | NCT04724980 | Recurrent Respi... Papillomavirus ... Papillomavirida... | PRGN-2012 | 18 Years - | Precigen, Inc | |
| Phase I Trial of BAY1251152 for Advanced Blood Cancers | NCT02745743 | Hematologic Neo... | BAY1251152 | 18 Years - | Bayer | |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05315167 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas | NCT01078649 | Cancer Solid Tumors Lymphoma Malignancy | Debio 1143 (AT-... | 18 Years - | Debiopharm International SA | |
| PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | NCT03460977 | Castration Resi... Small Cell Lung... Follicular Lymp... | PF-06821497 | 18 Years - | Pfizer | |
| A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors | NCT01299701 | Advanced Solid ... | ASA404 | 18 Years - | Novartis | |
| First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | NCT03681951 | Neoplasms, Panc... | GSK3145095 Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer | NCT03466424 | Radiation Oncol... Rectal Cancer | preoperative sh... | 18 Years - 70 Years | Fujian Medical University Union Hospital | |
| A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors | NCT01608867 | Solid Tumors | OMP-54F28 | 18 Years - 90 Years | Mereo BioPharma | |
| A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | NCT01677741 | Neoplasms, Brai... | Dabrafenib | 12 Months - 17 Years | Novartis | |
| JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors | NCT02904226 | Cancer | JTX-2011 Nivolumab Ipilimumab Pembrolizumab | 18 Years - | Jounce Therapeutics, Inc. | |
| A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC) | NCT00960167 | Hepatocellular ... | 3DCRT or IMRT | 18 Years - 70 Years | National Taiwan University Hospital | |
| PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | NCT03685591 | Breast Neoplasm... Prostate Neopla... Neoplasms, Squa... Melanoma Mesothelioma Pancreatic Neop... Colorectal Neop... Carcinoma, Rena... Liver Neoplasms | PF-06952229 Enzalutamide | 18 Years - | Pfizer | |
| Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | NCT01336842 | Solid Tumors Non-Small Cell ... | Panobinostat, C... | 18 Years - | University of California, Davis | |
| A Study of HMPL-453 in Patients With Advanced Solid Malignancies | NCT03160833 | Solid Tumor, Ad... | HMPL-453 | 25 Years - | Hutchmed | |
| A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors | NCT06143007 | Advanced Solid ... | BB3008 tablet | 18 Years - 78 Years | BrodenBio Co., Ltd. | |
| A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors | NCT00880321 | Cancer | GSK2118436 GSK2118436 Midazolam | 18 Years - | GlaxoSmithKline | |
| Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies | NCT01188252 | Neoplasms | Roniciclib (BAY... | 18 Years - | Bayer | |
| Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | NCT02134067 | Advanced Solid ... | TAS-119 Paclitaxel | 18 Years - | Taiho Oncology, Inc. | |
| Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 | NCT01008527 | Melanoma | CP 870,893 Peptides Oncovir poly IC... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | NCT04724980 | Recurrent Respi... Papillomavirus ... Papillomavirida... | PRGN-2012 | 18 Years - | Precigen, Inc | |
| Dose Escalated Adaptive RadioTherapy in Definitive Chemo-radiotherapy for Esophageal Cancer | NCT04086901 | Esophageal Canc... | Radiotherapy do... | 18 Years - | University of Aarhus | |
| A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment | NCT04811898 | Multiple Myelom... Hepatocarcinoma Advanced Solid ... | LNA-i-miR-221 | 18 Years - | Azienda Ospedaliera Universitaria Mater Domini, Catanzaro | |
| Multimodality- Adapted Dose Modification in Head and Neck Cancer Radiation Therapy  | NCT04933357 | Head and Neck C... | Dose escalation Standard dose | 18 Years - | National Cancer Institute, Egypt | |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552 | Primary Myelofi... Thrombocytosis Essential Throm... Polycythemia Ve... Myeloproliferat... Bone Marrow Dis... Hematologic Dis... Blood Coagulati... Blood Platelet ... Hemorrhagic Dis... | LDE225 INC424 | 18 Years - | Novartis | |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | NCT03665285 | Advanced or Met... Lung Cancer Breast Cancer Head and Neck S... Endometrial Can... Melanoma CRC Urothelial Carc... Cholangiocarcin... | NC318 | 18 Years - | NextCure, Inc. | |
| Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors | NCT04669899 | Cancer | JTX-8064 pimivalimab | 18 Years - | Jounce Therapeutics, Inc. | |
| Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors | NCT04446351 | Neoplasms | GSK6097608 Dostarlimab Cobolimab Belrestotug | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
